Q-omics provides the consensus-scored ANKRD62P1-PARP4P3 profile across patient tissues and cancer cell-line models. ANKRD62P1-PARP4P3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ANKRD62P1-PARP4P3 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, ANKRD62P1-PARP4P3 RNA expression shows 12,756 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where ANKRD62P1-PARP4P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD62P1-PARP4P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD62P1-PARP4P3 survival associations across molecular data types. ANKRD62P1-PARP4P3 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD62P1-PARP4P3 RNA expression–survival associations across cancer types. High ANKRD62P1-PARP4P3 expression shows unfavorable associations in UVM, READ, LIHC, KIRC and BLCA, but favorable associations in LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ANKRD62P1-PARP4P3 RNA expression.
This table summarizes ANKRD62P1-PARP4P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD62P1-PARP4P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD62P1-PARP4P3 shows lower tumor expression in KIRC, UCEC, KIRP, ESCA and LUSC and higher tumor expression in LUAD. The KIRC box plot shows higher ANKRD62P1-PARP4P3 RNA expression in normal versus tumor tissue (log2 FC = −0.142, t-test p < 0.001).
This table shows molecular features associated with ANKRD62P1-PARP4P3 in patient tissues and cancer cell lines. In patient samples, ANKRD62P1-PARP4P3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD62P1-PARP4P3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
